Inovio sticks with prostate cancer drug
Roche may have scuttled its prostate cancer collaboration with Inovio, but it hasn't shaken the latter company's confidence in its pipeline.
Instead, the Pennsylvania drugmaker said in a statement Monday that it would continue to develop its experimental immuno-oncology drug INO-5150, and said it expects to kick off Phase-I clinical trials in the first half of next year. The treatment targets both the prostate-specific membrane antigen as well as the prostate-specific antigen.
Inovio and Roche remain linked in the hepatitis B space, and will continue to develop INO-1800.